EMA Authorised: Usrenty (ustekinumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorised Usrenty (ustekinumab biosimilar) by Biosimilar Collaborations Ireland Limited for Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Usrenty (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 13/02/2026